November 9, 2022
The Globe and Mail | AbCellera posts another strong quarter of COVID-19 antibody sales – but new variants could affect 2023 revenue
AbCellera Biologics (NASDAQ: ABCL) Q3 2022 results coverage out now in the Globe and Mail with commentary from Bloom Burton equity research analyst Antonia Borovina:
